Bio­gen's Al San­drock says the FDA needs to ap­prove their con­tro­ver­sial Alzheimer's drug — now

Al San­drock is an out­spo­ken cham­pi­on for ad­u­canum­ab. And he clear­ly be­lieves that the FDA needs to ap­prove it now — over­rid­ing the con­tro­ver­sy it’s sparked — or face crit­i­cism from pa­tients clam­or­ing for some kind of med­ica­tion to slow the dis­ease.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE